The Swiss major is close to its first submission for ‘pipeline in a pill’ iptacopan but has conceded defeat with branaplam as a potential treatment for Huntington’s disease.

Roche will suffer a hangover from its COVID-19 successes this year as revenues stagnate and its future strategy is yet to be laid out by incoming CEO Thomas Schinecker.

Abbott’s US formula sales continued to fall during the October-December period on manufacturing disruptions even with production “up and running” at its Sturgis, MI, where it makes powder formula it markets under Similac, Alimentum and EleCare brands.

Roche remains the European sector’s biggest company despite a wobble in 2022, but Novo Nordisk’s spectacular growth has seen it overtake AstraZeneca and Novartis in market cap terms.